Education/Working Experience

Education

1999-2001: Department of Microbiology, University of Saskatchewan, Postdoctoral Research fellow, Specialty: Mutation of cytokine and therapy of the infectious diseases.

1996-1998: Laboratory of Molecular Immunology, Department of Immunology, Beijing Medical University, Postdoctoral Research fellow, Specialty: high activity and stability of cytokines.

1992-1995: Department of Microbiology, Institute of Epidemiology and Microbiology, Chinese Academy of Preventive Medicine, studying for Ph.D. Specialty: Genetics and Engineering of Lactic acid bacteria.

1986-1990: Department of Microecology, Dalian Medical University studying for Master Degree, Specialty: Microecology in gynecological and obstetric diseases.

1983-1986: Department of Microbiology, Dalian Medical University teaching for Medical Microbiology

1977-1982: Faculty of Medicine, Jinzhou Medical College studying for Bachelor of Medicine

Professional Experience

2001-present: Professor , Department of Immunology, Dalian Medical University

1987-1991: Lecturer, Department of Microbiology, Dalian Medical University

1982-1986: Assistant, Department of Microbiology, Dalian Medical University

Publication

1.Xin Lliu, Jing Peng, Wenchang Sun, Shufen Yang, Guoying Deng, Fang Li, Jya-wei Chen and John R. Gordon. G31P, an antagonist against CXC chemokine receptors 1 and 2, inhibits growth of human prostate cancer cells in nude mice. Tohoku J Exp. Med 2012, 228, 147~156
2.YuanHua Qin，FuShun Fan，Ying Zhao，Ying Cui，XiaoQing Wei，Kazuhiro Kohama，John R. Gordon，Fang Li，Ying Gao. Recombinant Human CXCL8(3-72)K11R/G31P Regulates Smooth Muscle Cell Proliferation and Migration Through Blockage of Interleukin-8 Receptor. 2013 Research Communication 65（1） 67~75

3.Jing Wei, Jing Peng, Bing Wang, Hong Qu, ShiyiWang, Aziz Faisal,Jia-Wei Cheng, John R. Gordon, and Fang Li. 2013. CXCR1/CXCR2 Antagonism Is Effective in Pulmonary Defense against Klebsiella pneumoniae Infection. BioMed Research International Volume, 1-6

4. Jing Wei,, Xiangyu Chen, Qiang Li, Jifei Chen, Noman Khan, Bing Wang, Jya-Wei Cheng, John R. Gordon and Fang. Li. ELR-CXC chemokine antagonism and cisplatin co-treatment additively reduce H22 hepatoma tumor progression , andameliorate cisplatin-induced nephrotoxicity  2014 Oncology reports 31: 1599-1604

5.Lingyun Li, Muhammad Noman Khan, Qiang Li, Xiangyu Chen, Jing Wei,Bing Wang, Jya -wei Cheng, John R. Gordon and Fang Li .G31P, CXCR1/2 inhibitor, with cisplatin inhibits the growth of mice hepatocellular carcinoma and mitigates high‑dose cisplatin-induced nephrotoxicity  2015 ONCOLOGY REPORTS 33: 751-757.

6.Muhammad Noman Khan, Bing Wang, Jing Wei, Yingqiu Zhang, Qiang Li, Xuelin Luan, Jya-wei Cheng, John R. Gordon, Fang Li, Han Liu CXCR1/2 antagonism with CXCL8/interleukin-8 analogue CXCL8(3-72 ) KIIR/G31P restrict lung cancer growth by inhibiting tumor cell proliferation angiogenesis. Oncotarget. 2015 June 10

8.Zhichao Ai, Wei Jing, Li Fang  Cytokine-Like Protein 1(Cytl1): A Potential

Molecular Mediator in Embryo Implantation. PLOS ONE | DOI:10.1371/journal.pone.0147424 January 22, 2016

Research Projects/Grants

1. 2006,1~2006,12   NSFC  The research of structure and antiinflammation of human entirely new high affinity antaganist to CXCR1/2  80,000 (RMB)

2.2005-08 NSERC Discovery Grant. ELR-CXC chemokines in bacterial inflammation.  10,000(Can)

3 2008,1~1010,12  NSFC The research of Anti-inflammation of human high affinity CXCR1/2 antignist  300,000 (RMB)

Admission Plan/Requirements

Mater degree 1, PhD 1